FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2889711380> ?p ?o ?g. }

• W2889711380 endingPage "560" @default.
• W2889711380 startingPage "550" @default.
• W2889711380 abstract "The substituted 1,8-Naphthalimides (1H-benzo[de]isoquinoline-1,3(2H)- diones) are known as DNA intercalators stabilizing DNA-Topoisomerase II complexes. This interaction disrupts the cleavage-relegation equilibrium of Topo II, resulting in formation of broken strands of DNA.To investigate the influence of type of substituents and substitution positions in 1,8- naphthalimde skeleton on the inhibition of Topoisomerase II activity.The starting 1,8-naphthalimide were prepared from acenaphthene by introduction of appropriate substituents followed by condensation with ω-hydroxylakylamines of different chain length. The substituents were introduced to 1,8-naphthalimide molecule by nucleophilic substitution of leaving groups like nitro or bromo present in 4 or 4,5- positions using the ω- hydroxylalkylamines. The bioactivity of obtained compounds was examined in model cell lines.Antiproliferative activity of selected compounds against HCT 116 human colon cancer cells, human non-small cell lung cells A549 and non-tumorigenic BEAS-2B human bronchial epithelium cells was examined. Several of investigated compounds exhibit a significant activity (IC50 µM to 7 µM) against model cancer cell lines. It was demonstrated that upon treatment with concentration of 200 µM, all derivatives display Topo II inhibitory activity, which may be compared with activity of Amonafide.The replacement of the nitro groups in the chromophore slightly reduces its anticancer activities, whereas the presence of both nitro group and ω-hydroxylalkylamine chain resulted in seriously increased anticancer activity. Obtained compounds showed Topo II inhibitory activity, moreover, influence of the substitution pattern on the ability to inhibit Topo II activity and cancer cells proliferation was observed." @default.
• W2889711380 created "2018-09-27" @default.
• W2889711380 creator A5008012644 @default.
• W2889711380 creator A5022442911 @default.
• W2889711380 creator A5022722100 @default.
• W2889711380 creator A5064233572 @default.
• W2889711380 creator A5069570976 @default.
• W2889711380 creator A5074101599 @default.
• W2889711380 date "2019-07-02" @default.
• W2889711380 modified "2023-10-18" @default.
• W2889711380 title "Anticancer Activity and Topoisomerase II Inhibition of Naphthalimides with ω-Hydroxylalkylamine Side-Chains of Different Lengths" @default.
• W2889711380 cites W1566199112 @default.
• W2889711380 cites W1979185936 @default.
• W2889711380 cites W1982859999 @default.
• W2889711380 cites W1987541017 @default.
• W2889711380 cites W1992395686 @default.
• W2889711380 cites W1999410266 @default.
• W2889711380 cites W2005152643 @default.
• W2889711380 cites W2011513452 @default.
• W2889711380 cites W2020162692 @default.
• W2889711380 cites W2033537472 @default.
• W2889711380 cites W2048572871 @default.
• W2889711380 cites W2049153208 @default.
• W2889711380 cites W2055392346 @default.
• W2889711380 cites W2070968982 @default.
• W2889711380 cites W2071440538 @default.
• W2889711380 cites W2074732735 @default.
• W2889711380 cites W2079636476 @default.
• W2889711380 cites W2167526365 @default.
• W2889711380 cites W2192456358 @default.
• W2889711380 cites W2308665141 @default.
• W2889711380 cites W2327637417 @default.
• W2889711380 cites W2332112418 @default.
• W2889711380 cites W2587934649 @default.
• W2889711380 cites W2949410232 @default.
• W2889711380 cites W344226922 @default.
• W2889711380 doi "https://doi.org/10.2174/1573406414666180912105851" @default.
• W2889711380 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30207241" @default.
• W2889711380 hasPublicationYear "2019" @default.
• W2889711380 type Work @default.
• W2889711380 sameAs 2889711380 @default.
• W2889711380 citedByCount "6" @default.
• W2889711380 countsByYear W28897113802021 @default.
• W2889711380 countsByYear W28897113802022 @default.
• W2889711380 countsByYear W28897113802023 @default.
• W2889711380 crossrefType "journal-article" @default.
• W2889711380 hasAuthorship W2889711380A5008012644 @default.
• W2889711380 hasAuthorship W2889711380A5022442911 @default.
• W2889711380 hasAuthorship W2889711380A5022722100 @default.
• W2889711380 hasAuthorship W2889711380A5064233572 @default.
• W2889711380 hasAuthorship W2889711380A5069570976 @default.
• W2889711380 hasAuthorship W2889711380A5074101599 @default.
• W2889711380 hasConcept C116073593 @default.
• W2889711380 hasConcept C135731615 @default.
• W2889711380 hasConcept C147897179 @default.
• W2889711380 hasConcept C151730666 @default.
• W2889711380 hasConcept C155647269 @default.
• W2889711380 hasConcept C175156509 @default.
• W2889711380 hasConcept C178790620 @default.
• W2889711380 hasConcept C185592680 @default.
• W2889711380 hasConcept C202751555 @default.
• W2889711380 hasConcept C2776923262 @default.
• W2889711380 hasConcept C2777752497 @default.
• W2889711380 hasConcept C2779707156 @default.
• W2889711380 hasConcept C2780263894 @default.
• W2889711380 hasConcept C2780639532 @default.
• W2889711380 hasConcept C43369102 @default.
• W2889711380 hasConcept C54355233 @default.
• W2889711380 hasConcept C552990157 @default.
• W2889711380 hasConcept C55493867 @default.
• W2889711380 hasConcept C62112901 @default.
• W2889711380 hasConcept C71240020 @default.
• W2889711380 hasConcept C81729549 @default.
• W2889711380 hasConcept C81885089 @default.
• W2889711380 hasConcept C86803240 @default.
• W2889711380 hasConceptScore W2889711380C116073593 @default.
• W2889711380 hasConceptScore W2889711380C135731615 @default.
• W2889711380 hasConceptScore W2889711380C147897179 @default.
• W2889711380 hasConceptScore W2889711380C151730666 @default.
• W2889711380 hasConceptScore W2889711380C155647269 @default.
• W2889711380 hasConceptScore W2889711380C175156509 @default.
• W2889711380 hasConceptScore W2889711380C178790620 @default.
• W2889711380 hasConceptScore W2889711380C185592680 @default.
• W2889711380 hasConceptScore W2889711380C202751555 @default.
• W2889711380 hasConceptScore W2889711380C2776923262 @default.
• W2889711380 hasConceptScore W2889711380C2777752497 @default.
• W2889711380 hasConceptScore W2889711380C2779707156 @default.
• W2889711380 hasConceptScore W2889711380C2780263894 @default.
• W2889711380 hasConceptScore W2889711380C2780639532 @default.
• W2889711380 hasConceptScore W2889711380C43369102 @default.
• W2889711380 hasConceptScore W2889711380C54355233 @default.
• W2889711380 hasConceptScore W2889711380C552990157 @default.
• W2889711380 hasConceptScore W2889711380C55493867 @default.
• W2889711380 hasConceptScore W2889711380C62112901 @default.
• W2889711380 hasConceptScore W2889711380C71240020 @default.
• W2889711380 hasConceptScore W2889711380C81729549 @default.
• W2889711380 hasConceptScore W2889711380C81885089 @default.
• W2889711380 hasConceptScore W2889711380C86803240 @default.

• next